CAS: 614-86-8; 3-(2,4-Dihydroxyphenyl)Acrylic Acid

上下游产品

7-hydroxy-2H-chromen-2-one 7-acetyloxycoumarin 2,4-dimethoxycinnamic acid malonic acid

📜2,4-二甲氧基肉桂酸置于三溴化硼体系中,用 二氯甲烷 作为反应溶剂,以44%的收率获得产物繖[形]酸
参考文献:Curcumin Recognizes A Unique Binding Site Of Tubulin
标题:Curcumin Recognizes A Unique Binding Site Of Tubulin
摘要:Although Curcumin Is Known For Its Anticarcinogenic Properties,The Exact Mechanism Of Its Action Or The Identity Of The Target Receptor Is Not Completely Understood. Studies On A Series Of Curcumin Analogues,Synthesized To Investigate Their Tubulin Binding Affinities And Tubulin Self-Assembly Inhibition,Showed That: (I) Curcumin Acts As A Bifunctional Ligand,(II) Analogues With Substitution At The Diketone And Acetylation Of The Terminal Phenolic Groups Of Curcumin Are Less Effective,(Iii) A Benzylidiene Derivative,Compound 7,Is More Effective Than Curcumin In Inhibiting Tubulin Self-Assembly. Cell-Based Studies Also Showed Compound 7 To Be More Effective Than Curcumin. Using Fluorescence Spectroscopy We Show That Curcumin Binds Tubulin 32 Angstrom Away From The Colchicine-Binding Site. Docking Studies Also Suggests That The Curcumin-Binding Site To Be Close To The Vinblastine-Binding Site. Structure-Activity Studies Suggest That The Tridented Nature Of Compound 7 Is Responsible For Its Higher Affinity For Tubulin Compared To Curcumin.
DOI:10.1021/jm2004046

专利信息

专利号:WO-0063152-A1
优先权日:1999-02-22
标题:Acetylated and related analogues of chicoric acid as hiv integrase inhibitors
发明人：BURKE TERRENCE R; ZHAIWEI LIN; ZHAO HE; NEAMATI NOURI; POMMIER YVES
权利人:US HEALTH; BURKE TERRENCE R; ZHAIWEI LIN; ZHAO HE; NEAMATI NOURI; POMMIER YVES
摘要:Chicoric acid analogues and derivatives have activity against HIV-1 integrase. The structural features that are required for this activity are elucidated by assaying these analogues and derivatives against HIV-1 integrase. Furthermore, methods of synthesis of the enantiomers of chicoric acid itself, as well as its analogues and derivatives, are disclosed. Additionally, methods of use of chicoric acid analogues and derivatives to inhibit HIV-1 integrase are disclosed, as are compositions comprising chicoric acid analogues and derivatives.

专利号:US-6150403-A
优先权日:1997-10-14
标 题 :Topical compositions for regulating the oily/shiny appearance of skin
发明人：BIEDERMANN KIMBERLY A; SCHUBERT HARRY L; PARRAN JR JOHN J
权利人:PROCTER & GAMBLE
摘要:The present invention relates to methods for inhibiting sebaceous gland activity in mammalian skin comprising administration of a topical composition comprising dehydroacetic acid or pharmaceutically acceptable salts thereof, and a dermatologically-acceptable carrier. The present invention also relates to methods and topical compositions further comprising agents which regulate the oily and/or shiny appearance of skin, and agents which treat acne and related skin disorders in mammalian skin and scalp. Methods of reducing sebum synthesis with the use of dehydroacetic acid, methods of regulating the oily and/or shiny appearance of skin, and methods of treating acne and other skin disorders are also encompassed by the present invention.

专利号:US-9115218-B2
优先权日:2010-02-09
标题:Anionic polysaccharides functionalized by at least two hydrophobic groups carried by an at least trivalent spacer
发明人：CHARVET RICHARD; SOULA REMI; SOULA OLIVIER
权利人:CHARVET RICHARD; SOULA REMI; SOULA OLIVIER; ADOCIA
摘要:Anionic polysaccharide derivatives partially functionalized by at least two vicinal hydrophobic groups, the hydrophobic groups, which are identical or different, being carried by an at least trivalent radical or spacer, a method of synthesis of the functionalized polysaccharides, and pharmaceutical compositions having one of the polysaccharides and at least one active principle are provided.

专利号:US-2013164265-A1
优先权日:2011-12-21
标题 :Skin care compositions
发明人：FLAVIN DANA; OBENLAND SIGRID
权利人:FLAVIN DANA; OBENLAND SIGRID
摘要:This invention provides compositions and methods of manufacturing such compositions that employ GRAS compounds which can act to promote the generation of stem, epidermal or other skin cells in the epidermis, activation of collagen synthesis, activation of hyaluronic acid synthesis, enhanced skin hydration, and dermal healing by stimulating stem cell and fibroblast migration to sites of needed repair. These compositions and methods are useful for rejuvenating the skin and for treating some skin-related aging or other dermal damaging conditions, including wrinkle reduction and treatment of minor dermal wounds.

专利号:US-2014328952-A1
优先权日:2011-12-21
标题:Topical compositions
发明人：FLAVIN DANA
权利人:FLAVIN DANA
摘要:This invention provides compositions and methods of manufacturing such compositions that employ GRAS compounds which can act to promote the generation of stem, epidermal or other skin cells in the epidermis, activation of collagen synthesis, activation of hyaluronic acid synthesis, enhanced skin hydration, and dermal healing by stimulating stem cell and fibroblast migration to sites of needed repair. These compositions and methods are useful for rejuvenating the skin and for treating some skin-related aging or other dermal damaging conditions, including wrinkle reduction and treatment of minor dermal wounds.

专利号:US-10584156-B2
优先权日:2015-03-13
标 题:Insulin analogues with a glucose-regulated conformational switch
发明人：WEISS MICHAEL
权利人:UNIV CASE WESTERN RESERVE
摘要:A two-chain insulin analogue contains an A chain modified by (i) a monomeric glucose-binding element at or near its N terminus and (ii) a B chain modified by at or near its C terminus by an element that reversibly binds to the monomeric glucose-binding element such that this linkage is displaceable by glucose. The monomeric glucose-binding element may be phenylboronic acid derivative (optionally halogenated). The B chain may be modified by a diol-containing element derived from a monosaccharide, disaccharide or oligosaccharide, a non-saccharide diol-containing moiety or a α-hydroxycarboxylate-containing moiety. The analogue can be manufactured by trypsin-mediated semi-synthesis. Formulations can be at strengths U-10 to U-1000 in soluble solutions at pH 7.0-8.0 with or without zinc ions at a molar ratio of 0.0-3.0 ions per insulin analogue monomer. A patient with diabetes mellitus may be treated with subcutaneous, intraperitoneal, or oral administration of a physiologically effective amount of the insulin analogue.